Instil Bio Reports Promising Phase 2 Study Results

The latest announcement is out from Instil Bio ( (TIL) ).

On July 31, 2025, Instil Bio, Inc. reported that ImmuneOnco Biopharmaceuticals announced preliminary safety and efficacy data from a Phase 2 study of IMM2510/AXN-2510 in combination with chemotherapy for advanced non-small cell lung cancer in China. The study showed partial responses in 62% of efficacy evaluable patients, with no dose-limiting toxicities observed. The data suggests promising safety and efficacy outcomes, potentially impacting treatment options for advanced NSCLC.

The most recent analyst rating on (TIL) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Instil Bio stock, see the TIL Stock Forecast page.

Spark’s Take on TIL Stock

According to Spark, TipRanks’ AI Analyst, TIL is a Underperform.

Instil Bio’s stock faces considerable challenges primarily due to severe financial instability, as evidenced by the absence of revenue and ongoing losses. The technical analysis indicates a bearish trend, with the stock significantly underperforming compared to its moving averages. Additionally, the company’s valuation metrics, including a negative P/E ratio and no dividend yield, further underscore the high risk associated with this investment. These factors combine to give Instil Bio a low overall stock score.

To see Spark’s full report on TIL stock, click here.

More about Instil Bio

Average Trading Volume: 312,950

Technical Sentiment Signal: Buy

Current Market Cap: $185.4M

Learn more about TIL stock on TipRanks’ Stock Analysis page.